---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-25-000029"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T06:38:17.306732+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# West Q1 sales $698M (+0.4%), adj. EPS $1.45; raises FY2025 net sales and adj. EPS guidance

## Summary
- Net sales $698.0M (+0.4% reported, +2.1% organic); reported EPS $1.23 vs $1.55 YoY; adj. EPS $1.45 vs $1.56 YoY.
- Full-year 2025 net sales guidance raised to $2.945B-$2.975B (prior $2.875B-$2.905B); adj. EPS guidance raised to $6.15-$6.35 (prior $6.00-$6.20).
- Q3 2025 dividend declared at $0.21/share, payable Aug 6, 2025 to holders of record July 30, 2025.
- Free cash flow $58.1M (up from $27.6M YoY); repurchased 550,281 shares for $133.5M in Q1.
- Guidance includes $20-25M net impact from tariffs; organic net sales growth expected ~2%-3% for FY2025.

## SEC filing metadata
- accession: 0000105770-25-000029
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577025000029/0000105770-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577025000029/wst-20250424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-25-000029
- JSON: https://secwatch.observer/filing/0000105770-25-000029.json
- Plain text: https://secwatch.observer/filing/0000105770-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.